Analysis of biologic surrogate markers from a children's oncology group phase I trial of gefitinib in pediatric patients with solid tumors

Antonio Jimeno, Najat C. Daw, Maria L. Amador, George Cusatis, Peter Kulesza, Mark Krailo, Ashish M. Ingle, Susan M. Blaney, Peter Adamson, Manuel Hidalgo

Research output: Contribution to journalArticlepeer-review

Abstract

This trial evaluated the effect of gefitinib on the plasma circulating levels of epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMP)-2 and -9 of patients treated on a pediatric Phase I trial. Complete plasma correlative studies were obtained from 16 of the 25 enrolled patients. There was a trend for lower MMP-2 baseline levels in patients with partial response or stable disease. The Ewing sarcoma from the only patient with partial response lacked egfr mutations. Gefitinib did not induce any significant variation in the levels of the assessed parameters, and none of these determinations showed significant predictive or prognostic value.

Original languageEnglish (US)
Pages (from-to)352-357
Number of pages6
JournalPediatric Blood and Cancer
Volume49
Issue number3
DOIs
StatePublished - Sep 2007

Keywords

  • EGFR
  • Gefitinib
  • MMP-2
  • MMP-9
  • VEGF

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Analysis of biologic surrogate markers from a children's oncology group phase I trial of gefitinib in pediatric patients with solid tumors'. Together they form a unique fingerprint.

Cite this